Purpura, Thrombocytopenic, Idiopathic Clinical Trial
Official title:
A Randomized, Double Blind, Placebo Controlled Pilot Trial of Rituximab for Non-splenectomized Adults With Acute Immune Thrombocytopenic Purpura Receiving Standard Treatment (R-ITP)
The purpose of this study is to assess the feasibility of a randomized, double blind, placebo controlled trial of add-on rituximab for non-splenectomized adults with acute immune thrombocytopenic purpura (ITP).
Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by severe
thrombocytopenia and bleeding. With current standard therapies, adult-onset ITP tends to
recur thus exposing patients to prolonged risks of hemorrhage and toxicities of standard
treatments. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be
effectively raise the platelet count in some patients with ITP and there is clinical and
biological evidence to suggest that, if given early, rituximab may prevent ITP relapses.
We have designed a randomized, double blind, placebo controlled pilot trial of rituximab for
the treatment of non-splenectomized adults with acute ITP who are receiving standard
treatments. The primary objectives of this trial are to determine the feasibility of
recruitment, randomization and blinding; the safety of rituximab in ITP; and the event rate
in the control group which will be used to calculate the sample size for a larger trial.
Secondary objectives are to determine rates of 6-month event free survival where an event is
defined as any of: a platelet count <50; the need for rescue treatment; or significant
bleeding. Data from this pilot trial will inform the design of a larger phase III trial.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01356511 -
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
|
Phase 4 | |
| Completed |
NCT00540423 -
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Not yet recruiting |
NCT03252457 -
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
|
Phase 3 | |
| Completed |
NCT00151840 -
Efficacy and Safety of IVIG-L in ITP Patients
|
Phase 3 | |
| Recruiting |
NCT05438875 -
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
|
Phase 3 | |
| Completed |
NCT02281370 -
Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT00547066 -
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
|
Phase 1/Phase 2 | |
| Completed |
NCT00370331 -
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
|
Phase 3 | |
| Completed |
NCT00828750 -
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Completed |
NCT00487968 -
Eltrombopag Taste Testing in Healthy Adult Volunteers
|
Phase 1 | |
| Withdrawn |
NCT01317966 -
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
|
N/A | |
| Not yet recruiting |
NCT03443570 -
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
|
Phase 3 | |
| Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
| Completed |
NCT02201290 -
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Completed |
NCT00220727 -
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
|
Phase 2 | |
| Completed |
NCT02334813 -
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
|
Phase 3 | |
| Completed |
NCT02891109 -
Regulatory B Cells and Chronic Immune Thrombocytopenia
|
N/A | |
| Completed |
NCT00706342 -
Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
| Completed |
NCT03258866 -
The Study of Different Dose Rituximab in the Treatment of ITP
|
Phase 4 | |
| Completed |
NCT01327872 -
Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects
|
Phase 1 |